Indivior (NASDAQ:INDV) on Monday said that it will cancel its secondary listing on the London Stock Exchange, effective July ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Indivior (INDV – Research Report) today and set a price target of $13.00. The company’s shares opened today at ...

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Indivior (INDV – Research Report). The company’s shares opened today at p988.50. C ...

As it works to send opioid use disorder (OUD) treatment Sublocade back into its prior growth territory, Indivior is switching ...

Drugmaker Indivior has announced plans to cancel its secondary listing in London, just a year after moving its primary ...

Indivior is set to delist from the London Stock Exchange after a sharp decline in the value of its shares and a management ...

Investing.com -- Indivior (LON: INDV) on Monday said it will delist from the London Stock Exchange (LON: LSEG) on July 25, ...

Indivior said it would cancel its listing on the London Stock Exchange and keep its primary listing on New York City's Nasdaq stock exchange.

Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. In this role, Barry will lead the company's commercial growth strategy, ...

Indivior, a pharmaceutical firm specializing in opioid addiction treatments, plans to delist from the London Stock Exchange ...

Australian biotech TekCyte Limited appointed a new co-CEO leadership team consisting of Tony Simula, TekCyte’s founding CEO, as well as Tara James, a commercial strategist and founder of Small and ...

(Reuters) -Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and ...